ReviewCurrent allergy and asthma reports2018
Severe Atopic Dermatitis in Children.
Review in Current allergy and asthma reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Efficacy and Safety of Omalizumab for the Treatment of Severe or Poorly Controlled Allergic Diseases in Children: A Systematic Review and Meta-Analysis.Frontiers in pediatrics · 2022Pooled it
- Clinical curative effect and quality of life evaluation of dupilumab in treating children with atopic dermatitis and its effect on IgE levels, eosinophil count, Th2 cytokines (IL-4 and IL-13), and thymus and activation-regulated chemokine.Postepy dermatologii i alergologii · 2025Article
- [Inflammatory dermatoses in children and adolescents : Diagnosis and treatment of atopic dermatitis and psoriasis].Dermatologie (Heidelberg, Germany) · 2024Review
- Atopic dermatitis in Ethiopian children: a multicenter study of clinical severity, characteristics, and sociodemographic factors.Frontiers in medicine · 2024Article
- Atopic Dermatitis in Italian Pre-School Children: Literature Review of Epidemiological Data with a Focus on Disease Prevalence and Severity.Children (Basel, Switzerland) · 2023Review
- Efficacy of probiotics in pediatric atopic dermatitis: A systematic review and meta-analysis.Clinical and translational allergy · 2023Review
- Impact of the Family and Household Environment on Pediatric Atopic Dermatitis in Japan.Journal of clinical medicine · 2023Article
- Probing the Skin-Brain Axis: New Vistas Using Mouse Models.International journal of molecular sciences · 2022Review
- Elevation of IgE in patients with psoriasis: Is it a paradoxical phenomenon?Frontiers in medicine · 2022Review
- Flare management in atopic dermatitis: from definition to treatment.Therapeutic advances in chronic disease · 2022Review
- Unmet Medical Needs and Early Referral of Pediatric Atopic Dermatitis: An Expert Modified Delphi Consensus from Saudi Arabia.Dermatology research and practice · 2022Article
- What plays a role in the severity of atopic dermatitis in children?Turkish journal of medical sciences · 2021Article
- Skin manifestations in pediatric patients with primary immunodeficiency diseases (PIDs) in a tertiary care hospital in Colombia.The World Allergy Organization journal · 2021Article
- Childhood atopic dermatitis: current developments, treatment approaches, and future expectationsTurkish journal of medical sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewSevere atopic dermatitis (AD) in childhood leads to significant morbidity including psychosocial problems and infectious complications. There are only a few approved treatment options for these patients. These include topical corticosteroids and tacrolimus ointment, which are associated with potential side effects. RECENT
findingsIn order to find better and safer treatments, further understanding of AD mechanisms is needed. Primary skin barrier defects play an important role in the pathogenesis of AD. In addition, the suppression of skin barrier functions by Th2 inflammation also plays an important role in the persistence and recurrence of AD. Cytokines in the Th2 pathway, which includes IL-4, IL-13, TSLP, IL-25, IL-31, and IL-33, are potential therapeutic targets in AD. Other potential targets of AD are Janus kinase, phospholipase A2, aryl hydrocarbon receptor, and skin microbiota. A better understanding of the pathogenesis of AD will provide future direction for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.